Literature DB >> 15365000

Use of the MagNA pure LC automated nucleic acid extraction system followed by real-time reverse transcription-PCR for ultrasensitive quantitation of hepatitis C virus RNA.

Linda Cook1, Ka-Wing Ng, Arthur Bagabag, Lawrence Corey, Keith R Jerome.   

Abstract

Hepatitis C virus (HCV) infection is an increasing health problem worldwide. Quantitative assays for HCV viral load are valuable in predicting response to therapy and for following treatment efficacy. Unfortunately, most quantitative tests for HCV RNA are limited by poor sensitivity. We have developed a convenient, highly sensitive real-time reverse transcription-PCR assay for HCV RNA. The assay amplifies a portion of the 5' untranslated region of HCV, which is then quantitated using the TaqMan 7700 detection system. Extraction of viral RNA for our assay is fully automated with the MagNA Pure LC extraction system (Roche). Our assay has a 100% detection rate for samples containing 50 IU of HCV RNA/ml and is linear up to viral loads of at least 10(9) IU/ml. The assay detects genotypes 1a, 2a, and 3a with equal efficiency. Quantitative results by our assay correlate well with HCV viral load as determined by the Bayer VERSANT HCV RNA 3.0 bDNA assay. In clinical use, our assay is highly reproducible, with high and low control specimens showing a coefficient of variation for the logarithmic result of 2.8 and 7.0%, respectively. The combination of reproducibility, extreme sensitivity, and ease of performance makes this assay an attractive option for routine HCV viral load testing.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15365000      PMCID: PMC516293          DOI: 10.1128/JCM.42.9.4130-4136.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

2.  Quantification of hepatitis C virus in human liver and serum samples by using LightCycler reverse transcriptase PCR.

Authors:  Peter A White; Yong Pan; Anthony J Freeman; George Marinos; Rosemary A Ffrench; Andrew R Lloyd; William D Rawlinson
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

3.  Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay.

Authors:  Marcel Beld; Roel Sentjens; Sjoerd Rebers; Christine Weegink; Jan Weel; Cees Sol; René Boom
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

4.  Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum.

Authors:  Pascale Trimoulet; Philippe Halfon; Eric Pohier; Hacène Khiri; Geneviève Chêne; Hervé Fleury
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

5.  Quantitative method of intracellular hepatitis C virus RNA using LightCycler PCR.

Authors:  Akito Nozaki; Nobuyuki Kato
Journal:  Acta Med Okayama       Date:  2002-04       Impact factor: 0.892

6.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  Real-time RT-PCR for quantitation of hepatitis C virus RNA.

Authors:  Ji Hong Yang; Jian Ping Lai; Steven D Douglas; David Metzger; Xian Hua Zhu; Wen Zhe Ho
Journal:  J Virol Methods       Date:  2002-04       Impact factor: 2.014

8.  High-throughput HBV DNA and HCV RNA detection system using a nucleic acid purification robot and real-time detection PCR: its application to analysis of posttransfusion hepatitis.

Authors:  Shigeki Mitsunaga; Kayoko Fujimura; Chieko Matsumoto; Rieko Shiozawa; Shinichi Hirakawa; Kazunori Nakajima; Kenji Tadokoro; Takeo Juji
Journal:  Transfusion       Date:  2002-01       Impact factor: 3.157

9.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

10.  Sensitivity and reproducibility of HCV quantitation in chimpanzee sera using TaqMan real-time PCR assay.

Authors:  Montserrat Puig; Kathleen Mihalik; Mei-ying Yu; Stephen M Feinstone; Marian E Major
Journal:  J Virol Methods       Date:  2002-09       Impact factor: 2.014

View more
  13 in total

1.  Primer sequence modification enhances hepatitis C virus genotype coverage.

Authors:  Yi-Wei Tang; Susan E Sefers; Haijing Li
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

2.  Relationships between hepatitis C virus replication and CXCL-8 production in vitro.

Authors:  Bon Chang A Koo; Paula McPoland; Jessica P Wagoner; Olivia J Kane; Volker Lohmann; Stephen J Polyak
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

3.  Pooling nasopharyngeal/throat swab specimens to increase testing capacity for influenza viruses by PCR.

Authors:  Tam T Van; Joseph Miller; David M Warshauer; Erik Reisdorf; Daniel Jernigan; Rosemary Humes; Peter A Shult
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

4.  Automated extraction of viral-pathogen RNA and DNA for high-throughput quantitative real-time PCR.

Authors:  Kurt Beuselinck; Marc van Ranst; J van Eldere
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

5.  Naturally occurring genotype 2b/1a hepatitis C virus in the United States.

Authors:  Dipankar Bhattacharya; Molly A Accola; Israr H Ansari; Rob Striker; William M Rehrauer
Journal:  Virol J       Date:  2011-10-03       Impact factor: 4.099

6.  Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay.

Authors:  Christophe Ronsin; Anne Pillet; Corinne Bali; Gérard-Antoine Denoyel
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

7.  Effect of cell polarization on hepatitis C virus entry.

Authors:  Christopher J Mee; Joe Grove; Helen J Harris; Ke Hu; Peter Balfe; Jane A McKeating
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

8.  Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity.

Authors:  Michelle J Farquhar; Helen J Harris; Mandy Diskar; Sarah Jones; Christopher J Mee; Søren U Nielsen; Claire L Brimacombe; Sonia Molina; Geoffrey L Toms; Patrick Maurel; John Howl; Friedrich W Herberg; Sven C D van Ijzendoorn; Peter Balfe; Jane A McKeating
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

9.  Intrahepatic hepatitis C virus replication correlates with chronic hepatitis C disease severity in vivo.

Authors:  Sampa Pal; Margaret C Shuhart; Lisa Thomassen; Scott S Emerson; Tao Su; Nathan Feuerborn; John Kae; David R Gretch
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

10.  Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies.

Authors:  Joe Grove; Søren Nielsen; Jin Zhong; Margaret F Bassendine; Heidi E Drummer; Peter Balfe; Jane A McKeating
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.